We recently published a list of Billionaire Ken Griffin’s 10 Midcap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against Billionaire Ken Griffin’s other midcap stock picks with huge upside potential.
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry. Ken Griffin tasted early success while trading during his college days, and it is safe to say that he has never looked back since. Despite huge setbacks during the financial crisis of 2008, he used his skills and determination to make a comeback where many others would have simply closed the fund and moved on.
The billionaire investor currently manages assets worth around $65 billion across his funds. Owing to its large size and track record of success, Ken Griffin’s stock moves often make it to the news and are closely followed by investors. We decided to do the same, focusing on Mid-cap stocks that still had the potential to turn into established giants tomorrow.
To come up with the list of billionaire Ken Griffin’s 10 midcap stock picks with huge upside potential, we looked at his latest 13F holdings and, among his significant holdings, only considered stocks between $10 billion and $40 billion in market cap. We then looked at the average analyst price target on Wall Street and ranked the stocks according to their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A healthcare professional discussing treatment options for a patient with a neurological disorder.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Stock Upside Potential: 45.88%
Citadel Investment Group’s Stake: $346,451,879
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) operates as a developer, discoverer, and marketer of pharmaceuticals for neuroendocrine, neuropsychiatric, and neurological disorders. Its major product candidates include INGREZZA, Efmody capsules, Orilissa tablets, Oriahnn capsules, ALKINDI, and CRENESSITY.
The firm was upgraded by RBC Capital Markets from Sector Perform to Outperform, highlighting the recent market downturn as an attractive buying opportunity. However, the price target was adjusted by RBC analyst Brian Abrahams from $138 to $137, anticipating short-term fluctuations due to the latest quarter earnings and long-term uncertainty surrounding Medicare drug price talks.
RBC analysts think that the current share price is a good entry point for investors looking for a reliable biotech.
RBC Capital Markets’ analyst Brian Abrahams stated:
Broader sector selloff and market downside has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) also reaffirmed its 2025 guidance after beating top-line estimates in the most recent quarter. Aided by ongoing direct-to-consumer initiatives and an expanded sales force, Neurocrine anticipates INGREZZA sales to reach $2.5 billion to $2.6 billion for the full year. Regardless of potential competition, this guidance demonstrates continued growth. Due to clinical adoption factors and delays in reimbursement processes, the company expects CRENESSITY’s revenue to increase gradually. Moreover, Phase 3 trials for osavampator and NBI-568 are ongoing, with the firm setting aside $60 million to advance its product pipeline during 2025.
Overall, NBIX ranks 4th on our list of Billionaire Ken Griffin’s midcap stock picks with huge upside potential. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
